A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC

Inclusion Criteria

• •Is at least 18 years of age and the local legal age of consent
• •Is diagnosed with CIDP (confirmed or possible CIDP) according to the criteria of the European Academy of Neurology/Peripheral Nerve Society
• •Is being treated with IVIg every 3-6 weeks, on a stable dose and dosing interval (between 0.5-2 g/kg) for at least 3 doses
• •If receiving oral corticosteroids, this should be at a stable dose of less than 20 mg a day or less than 40 mg every other day, for at least a month.
• •If receiving nonsteroidal immunosuppressive medication, this should be at a stable dose for at least 3 months